| payload |
{"created_at":"2026-04-17T02:13:18.114 {"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:8d5d7246868c7278","evidence_event_ids":["evt_318af0dd14e0"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","company":"Tango Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","article_chars":2014,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_36142f288cba104d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:43:09.962661+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt","source_event_id":"evt_318af0dd14e0","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"747dd44ae4458d02","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-16","2026-04-15","2025-10-27","2024-02-27","2026-03-01","2026-04-15","2026-04-16","20200723","2026-04-15"],"entities":[{"asset_class":"equity","name":"Tango Therapeutics, Inc.","relevance":"high","symbol":"TNGX","type":"issuer"},{"asset_class":"person","name":"Crystal Adam","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"other","name":"C4 THERAPEUTICS, INC.","relevance":"low","symbol":"","type":"mail_address_entity"}],"event_type":"listing","information_gaps":["The cleaned text does not clearly show the specific transaction type(s) (e.g., buy/sell) and the exact number of shares/options transacted; it includes fragments like \u201cCommon Stock\u201d and \u201cStock Option (Right to Buy)\u201d but lacks a fully readable transaction table.","The signal is labeled \u201cdiscovery_sec_filing_delta,\u201d but no prior known state or comparison details are provided in the input, so \u201cwhat changed vs prior\u201d cannot be determined from the provided text alone.","The filing\u2019s \u201cmaterial_items\u201d are empty in the deterministic context, so no additional item-level guidance/implications are available beyond the vesting and Rule 10b5-1 statement."],"key_facts":["SEC filing accession number: 0001193125-26-159747.","Form type: 4 (Form 4).","Issuer: Tango Therapeutics, Inc. (TNGX).","Filed as of date: 2026-04-16; conform ed period of report: 2026-04-15.","Reporting owner: Crystal Adam; role shown as President, R&D.","The filing states: \u201cThese transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.\u201d","The filing states option vesting/exercisability over a four-year period: \u201c25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.\u201d","Signature line: \u201c/s/ Julie Fogarty, as attorney-in-fact\u201d dated 2026-04-16."],"numeric_claims":[{"label":"Option vesting schedule - initial tranche","value":"25% on 2024-02-27"},{"label":"Option vesting schedule - remaining tranche","value":"36 equal monthly installments thereafter"},{"label":"Rule 10b5-1 plan adoption date","value":"2025-10-27"},{"label":"Conformed period of report","value":"2026-04-15"},{"label":"Filed as of date","value":"2026-04-16"}],"primary_claim":"Tango Therapeutics, Inc. filed Form 4 (accession 0001193125-26-159747) on 2026-04-16 for transactions dated 2026-04-15 by reporting owner Crystal Adam under a Rule 10b5-1 trading plan.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Tango Therapeutics, Inc. (TNGX) filed a Form 4 on 2026-04-16 covering transactions with reporting owner Crystal Adam for the period ending 2026-04-15. The filing states the transactions were executed under a Rule 10b5-1 trading plan and describes option vesting terms.","topics":["SEC Form 4","insider transactions","Rule 10b5-1 trading plan","stock option vesting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Tango Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TNGX","tickers":["TNGX"],"title":"TNGX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-159747.txt"}}... |